NCT04238208 - The Efficacy and Safety Profile of Capsaicin 8% Patch Versus 5% Lidocaine Patch in Males With Diabetic Neuropathy | Biotech Hunter

Enrollment

290

Participants

Timeline

Start Date

January 10, 2019

Primary Completion Date

December 10, 2019

Study Completion Date

January 2, 2020

Conditions

Diabetic Nerve ProblemsDiabetic NeuropathyDiabetic Complications Neurological

Interventions

DRUG

Lidocaine 5% patch

5% lidocaine patch (Lidoderm®, Endo Pharmaceuticals Inc, Malvern, USA) 10 x 14 cm

DRUG

Capsaicin 8% Patch, Per 10 Square Centimeters

8% Capsaicin patch \[8% w/w\] 640 µg/cm² of adhesive, patch area 280 cm2 (20 cm x 14 cm), (Qutenza®; capsaicin 179 mg patch, Astella Pharma Europe Ltd. Chertsey, UK)

Trial Locations (1)

Unknown

Zainab Khan, Lahore